Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...

Takeda and Protagonist Therapeutics have reported positive topline outcomes from their Phase III VERIFY trial of rusfertide ...

Hastings Public Schools Foundation, Mary Lanning Healthcare Foundation, and Central Community College have all agreed to ...

Rusfertide outperformed placebo in polycythemia vera, meeting all primary and secondary end points in the phase 3 VERIFY ...

Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 V ...

Tuition, fees, textbooks, uniforms, equipment, and certification exams are covered for qualified students under a grant.

This phlebotomy training programme in adult venepuncture will incorporate academic learning in addition to practical application. The period of training lasts up to 3 months, leading to an assessment ...

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced the acquisition of PTI Health, a ...